A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders
Abstract Background Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested...
Gespeichert in:
Veröffentlicht in: | The international journal of neuropsychopharmacology 2021-09, Vol.24 (9), p.734-748 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 748 |
---|---|
container_issue | 9 |
container_start_page | 734 |
container_title | The international journal of neuropsychopharmacology |
container_volume | 24 |
creator | Romero-Miguel, Diego Casquero-Veiga, Marta MacDowell, Karina S Torres-Sanchez, Sonia Garcia-Partida, José Antonio Lamanna-Rama, Nicolás Romero-Miranda, Ana Berrocoso, Esther Leza, Juan C Desco, Manuel Soto-Montenegro, María Luisa |
description | Abstract
Background
Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model.
Methods
On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue.
Results
MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen).
Conclusions
MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains. |
doi_str_mv | 10.1093/ijnp/pyab036 |
format | Article |
fullrecord | <record><control><sourceid>oup_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8453277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ijnp/pyab036</oup_id><sourcerecordid>10.1093/ijnp/pyab036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0Eon_gxhn5xmVD7bXjJBek7bZApS5Fopwjx550XTl2ZDsrls_ZD4TDlgounDyWf_PejB9Cbyh5T0nDzsy9G8_GvewIE8_QMeWiKUpK6fPfNS0oL6sjdBLjPSFLXjLxEh0xTkVZUnGMHlZ4vZVBqgTB_JTJeId9j9MW8GXfg0pxvm6M82qvrHGAbwPINIBL-GIKxt3hlfYWogKnAOfubylMKk1B2gXeQJKdt0YtsHQa3_wwOlvsYIYgRvw1Ow-QrSM2Dku8kbl20uKrYZjcjJlhsoepNl6DnYf5AlPI9Q6sH-c5Mn4eZO6_MNEHncVeoRe9tBFeP56n6PvHy9v15-L65tPVenVdqLx_KijVBDreEMjfVVUS-r4qG14KIKzXinSq1pTXXSe5EHSpeMcYo6opRSNYXQt2ij4cdMepG0DnL0h57XYMZpBh33pp2n9fnNm2d37X1jmHZVVlgcVBQAUfY4D-qZeSdk63ndNtH9PN-Nu__Z7gP3Fm4N0B8NP4f6lfbom2Jg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</creator><creatorcontrib>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</creatorcontrib><description>Abstract
Background
Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model.
Methods
On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue.
Results
MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen).
Conclusions
MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</description><identifier>ISSN: 1461-1457</identifier><identifier>EISSN: 1469-5111</identifier><identifier>DOI: 10.1093/ijnp/pyab036</identifier><identifier>PMID: 34165516</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Animals ; Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - pharmacology ; Antioxidants - administration & dosage ; Antioxidants - pharmacology ; Behavior, Animal - drug effects ; Brain Diseases, Metabolic - drug therapy ; Brain Diseases, Metabolic - etiology ; Disease Models, Animal ; Female ; Magnetic Resonance Imaging ; Male ; Minocycline - administration & dosage ; Minocycline - pharmacology ; Nervous System Malformations - diagnostic imaging ; Nervous System Malformations - etiology ; Nervous System Malformations - pathology ; Neurodevelopmental Disorders - chemically induced ; Neurodevelopmental Disorders - drug therapy ; Neurodevelopmental Disorders - immunology ; Oxidative Stress - drug effects ; Positron-Emission Tomography ; Pregnancy ; Prenatal Exposure Delayed Effects - chemically induced ; Prenatal Exposure Delayed Effects - drug therapy ; Prenatal Exposure Delayed Effects - immunology ; Prepulse Inhibition - drug effects ; Rats ; Rats, Wistar ; Regular s ; Schizophrenia - chemically induced ; Schizophrenia - drug therapy ; Schizophrenia - immunology</subject><ispartof>The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.734-748</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of CINP. 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press on behalf of CINP.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</citedby><cites>FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453277/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453277/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1598,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34165516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romero-Miguel, Diego</creatorcontrib><creatorcontrib>Casquero-Veiga, Marta</creatorcontrib><creatorcontrib>MacDowell, Karina S</creatorcontrib><creatorcontrib>Torres-Sanchez, Sonia</creatorcontrib><creatorcontrib>Garcia-Partida, José Antonio</creatorcontrib><creatorcontrib>Lamanna-Rama, Nicolás</creatorcontrib><creatorcontrib>Romero-Miranda, Ana</creatorcontrib><creatorcontrib>Berrocoso, Esther</creatorcontrib><creatorcontrib>Leza, Juan C</creatorcontrib><creatorcontrib>Desco, Manuel</creatorcontrib><creatorcontrib>Soto-Montenegro, María Luisa</creatorcontrib><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><title>The international journal of neuropsychopharmacology</title><addtitle>Int J Neuropsychopharmacol</addtitle><description>Abstract
Background
Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model.
Methods
On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue.
Results
MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen).
Conclusions
MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Antioxidants - administration & dosage</subject><subject>Antioxidants - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>Brain Diseases, Metabolic - drug therapy</subject><subject>Brain Diseases, Metabolic - etiology</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Minocycline - administration & dosage</subject><subject>Minocycline - pharmacology</subject><subject>Nervous System Malformations - diagnostic imaging</subject><subject>Nervous System Malformations - etiology</subject><subject>Nervous System Malformations - pathology</subject><subject>Neurodevelopmental Disorders - chemically induced</subject><subject>Neurodevelopmental Disorders - drug therapy</subject><subject>Neurodevelopmental Disorders - immunology</subject><subject>Oxidative Stress - drug effects</subject><subject>Positron-Emission Tomography</subject><subject>Pregnancy</subject><subject>Prenatal Exposure Delayed Effects - chemically induced</subject><subject>Prenatal Exposure Delayed Effects - drug therapy</subject><subject>Prenatal Exposure Delayed Effects - immunology</subject><subject>Prepulse Inhibition - drug effects</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Regular s</subject><subject>Schizophrenia - chemically induced</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - immunology</subject><issn>1461-1457</issn><issn>1469-5111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0Eon_gxhn5xmVD7bXjJBek7bZApS5Fopwjx550XTl2ZDsrls_ZD4TDlgounDyWf_PejB9Cbyh5T0nDzsy9G8_GvewIE8_QMeWiKUpK6fPfNS0oL6sjdBLjPSFLXjLxEh0xTkVZUnGMHlZ4vZVBqgTB_JTJeId9j9MW8GXfg0pxvm6M82qvrHGAbwPINIBL-GIKxt3hlfYWogKnAOfubylMKk1B2gXeQJKdt0YtsHQa3_wwOlvsYIYgRvw1Ow-QrSM2Dku8kbl20uKrYZjcjJlhsoepNl6DnYf5AlPI9Q6sH-c5Mn4eZO6_MNEHncVeoRe9tBFeP56n6PvHy9v15-L65tPVenVdqLx_KijVBDreEMjfVVUS-r4qG14KIKzXinSq1pTXXSe5EHSpeMcYo6opRSNYXQt2ij4cdMepG0DnL0h57XYMZpBh33pp2n9fnNm2d37X1jmHZVVlgcVBQAUfY4D-qZeSdk63ndNtH9PN-Nu__Z7gP3Fm4N0B8NP4f6lfbom2Jg</recordid><startdate>20210921</startdate><enddate>20210921</enddate><creator>Romero-Miguel, Diego</creator><creator>Casquero-Veiga, Marta</creator><creator>MacDowell, Karina S</creator><creator>Torres-Sanchez, Sonia</creator><creator>Garcia-Partida, José Antonio</creator><creator>Lamanna-Rama, Nicolás</creator><creator>Romero-Miranda, Ana</creator><creator>Berrocoso, Esther</creator><creator>Leza, Juan C</creator><creator>Desco, Manuel</creator><creator>Soto-Montenegro, María Luisa</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20210921</creationdate><title>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</title><author>Romero-Miguel, Diego ; Casquero-Veiga, Marta ; MacDowell, Karina S ; Torres-Sanchez, Sonia ; Garcia-Partida, José Antonio ; Lamanna-Rama, Nicolás ; Romero-Miranda, Ana ; Berrocoso, Esther ; Leza, Juan C ; Desco, Manuel ; Soto-Montenegro, María Luisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-11d0eb490e11177aeff759456e03fdc0bc8d148bba46612c4b3331c9569638863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Antioxidants - administration & dosage</topic><topic>Antioxidants - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>Brain Diseases, Metabolic - drug therapy</topic><topic>Brain Diseases, Metabolic - etiology</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Minocycline - administration & dosage</topic><topic>Minocycline - pharmacology</topic><topic>Nervous System Malformations - diagnostic imaging</topic><topic>Nervous System Malformations - etiology</topic><topic>Nervous System Malformations - pathology</topic><topic>Neurodevelopmental Disorders - chemically induced</topic><topic>Neurodevelopmental Disorders - drug therapy</topic><topic>Neurodevelopmental Disorders - immunology</topic><topic>Oxidative Stress - drug effects</topic><topic>Positron-Emission Tomography</topic><topic>Pregnancy</topic><topic>Prenatal Exposure Delayed Effects - chemically induced</topic><topic>Prenatal Exposure Delayed Effects - drug therapy</topic><topic>Prenatal Exposure Delayed Effects - immunology</topic><topic>Prepulse Inhibition - drug effects</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Regular s</topic><topic>Schizophrenia - chemically induced</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romero-Miguel, Diego</creatorcontrib><creatorcontrib>Casquero-Veiga, Marta</creatorcontrib><creatorcontrib>MacDowell, Karina S</creatorcontrib><creatorcontrib>Torres-Sanchez, Sonia</creatorcontrib><creatorcontrib>Garcia-Partida, José Antonio</creatorcontrib><creatorcontrib>Lamanna-Rama, Nicolás</creatorcontrib><creatorcontrib>Romero-Miranda, Ana</creatorcontrib><creatorcontrib>Berrocoso, Esther</creatorcontrib><creatorcontrib>Leza, Juan C</creatorcontrib><creatorcontrib>Desco, Manuel</creatorcontrib><creatorcontrib>Soto-Montenegro, María Luisa</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The international journal of neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romero-Miguel, Diego</au><au>Casquero-Veiga, Marta</au><au>MacDowell, Karina S</au><au>Torres-Sanchez, Sonia</au><au>Garcia-Partida, José Antonio</au><au>Lamanna-Rama, Nicolás</au><au>Romero-Miranda, Ana</au><au>Berrocoso, Esther</au><au>Leza, Juan C</au><au>Desco, Manuel</au><au>Soto-Montenegro, María Luisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders</atitle><jtitle>The international journal of neuropsychopharmacology</jtitle><addtitle>Int J Neuropsychopharmacol</addtitle><date>2021-09-21</date><risdate>2021</risdate><volume>24</volume><issue>9</issue><spage>734</spage><epage>748</epage><pages>734-748</pages><issn>1461-1457</issn><eissn>1469-5111</eissn><abstract>Abstract
Background
Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model.
Methods
On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue.
Results
MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen).
Conclusions
MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>34165516</pmid><doi>10.1093/ijnp/pyab036</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1461-1457 |
ispartof | The international journal of neuropsychopharmacology, 2021-09, Vol.24 (9), p.734-748 |
issn | 1461-1457 1469-5111 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8453277 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Animals Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - pharmacology Antioxidants - administration & dosage Antioxidants - pharmacology Behavior, Animal - drug effects Brain Diseases, Metabolic - drug therapy Brain Diseases, Metabolic - etiology Disease Models, Animal Female Magnetic Resonance Imaging Male Minocycline - administration & dosage Minocycline - pharmacology Nervous System Malformations - diagnostic imaging Nervous System Malformations - etiology Nervous System Malformations - pathology Neurodevelopmental Disorders - chemically induced Neurodevelopmental Disorders - drug therapy Neurodevelopmental Disorders - immunology Oxidative Stress - drug effects Positron-Emission Tomography Pregnancy Prenatal Exposure Delayed Effects - chemically induced Prenatal Exposure Delayed Effects - drug therapy Prenatal Exposure Delayed Effects - immunology Prepulse Inhibition - drug effects Rats Rats, Wistar Regular s Schizophrenia - chemically induced Schizophrenia - drug therapy Schizophrenia - immunology |
title | A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T08%3A56%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Characterization%20of%20the%20Effects%20of%20Minocycline%20Treatment%20During%20Adolescence%20on%20Structural,%20Metabolic,%20and%20Oxidative%20Stress%20Parameters%20in%20a%20Maternal%20Immune%20Stimulation%20Model%20of%20Neurodevelopmental%20Brain%20Disorders&rft.jtitle=The%20international%20journal%20of%20neuropsychopharmacology&rft.au=Romero-Miguel,%20Diego&rft.date=2021-09-21&rft.volume=24&rft.issue=9&rft.spage=734&rft.epage=748&rft.pages=734-748&rft.issn=1461-1457&rft.eissn=1469-5111&rft_id=info:doi/10.1093/ijnp/pyab036&rft_dat=%3Coup_pubme%3E10.1093/ijnp/pyab036%3C/oup_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/34165516&rft_oup_id=10.1093/ijnp/pyab036&rfr_iscdi=true |